Sulfamethoxazole and Trimethoprim Oral Suspension, USP | Sulfamethoxazole and Trimethoprim
| Bacteria | TMP/SMX (1:19) | |||
|---|---|---|---|---|
| TMP Alone | SMX Alone | TMP | SMX | |
| * Rudoy RC, Nelson JD, Haltalin KC. Antimicrobial Agents and Chemotherapy. 1974;5:439-443. TMP = trimethoprim SMX = sulfamethoxazole |
||||
|
Escherichia coli
|
0.05 to 1.5 |
1 to 245 |
0.05 to 0.5 |
0.95 to 9.5 |
|
Escherichia coli (enterotoxigenic strains) |
0.015 to 0.15 |
0.285 to > 950 |
0.005 to 0.15 |
0.095 to 2.85 |
|
Proteus species (indole positive) |
0.5 to 5 |
7.35 to 300 |
0.05 to 1.5 |
0.95 to 28.5 |
|
Morganella morganii
|
0.5 to 5 |
7.35 to 300 |
0.05 to 1.5 |
0.95 to 28.5 |
|
Proteus mirabilis
|
0.5 to 1.5 |
7.35 to 30 |
0.05 to 0.15 |
0.95 to 2.85 |
|
Klebsiella species |
0.15 to 5 |
2.45 to 245 |
0.05 to 1.5 |
0.95 to 28.5 |
|
Enterobacter species |
0.15 to 5 |
2.45 to 245 |
0.05 to 1.5 |
0.95 to 28.5 |
|
Haemophilus influenzae
|
0.15 to 1.5 |
2.85 to 95 |
0.015 to 0.15 |
0.285 to 2.85 |
|
Streptococcus pneumoniae
|
0.15 to 1.5 |
7.35 to 24.5 |
0.05 to 0.15 |
0.95 to 2.85 |
|
Shigella flexneri*
|
< 0.01 to 0.04 |
< 0.16 to > 320 |
< 0.002 to 0.03 |
0.04 to 0.625 |
|
Shigella sonnei* |
0.02 to 0.08 |
0.625 to > 320 |
0.004 to 0.06 |
0.08 to 1.25 |
| Weight |
Dose - Every 12 Hours |
|
| lb |
kg |
Teaspoonfuls |
| 22 |
10 |
1 (5 mL) |
| 44 |
20 |
2 (10 mL) |
| 66 |
30 |
3 (15 mL) |
| 88 |
40 |
4 (20 mL) |
| Creatinine Clearance (mL/min) |
Recommended Dosage Regimen |
| Above 30 |
Use Standard Regimen |
| 15 to 30 |
½ the Usual Regimen |
| Below 15 |
Use Not Recommended |
| Weight |
Dose - Every 6 Hours |
|
| lb |
kg |
Teaspoonfuls |
| 18 |
8 |
1 (5 mL) |
| 35 |
16 |
2 (10 mL) |
| 53 |
24 |
3 (15 mL) |
| 70 |
32 |
4 (20 mL) |
| 88 |
40 |
5 (25 mL) |
| 106 |
48 |
6 (30 mL) |
| 141 |
64 |
8 (40 mL) |
| 176 |
80 |
10 (50 mL) |
| Body Surface Area |
Dose - Every 12 Hours |
| (m2) |
Teaspoonfuls |
| 0.26 |
½ (2.5 mL) |
| 0.53 |
1 (5 mL) |
| 1.06 |
2 (10 mL) |
Manufacturer
Aurobindo Pharma Limited
Active Ingredients
Source
- U.S. National Library of Medicine
- DailyMed
- Last Updated: 4 May 2013
Drugs and Medications
Sulfamethoxazole and trimethoprim [Teva Parenteral Medicines, Inc]
Sulfamethoxazole and Trimethoprim Injection, USP
Sulfamethoxazole and trimethoprim [Aurobindo Pharma Limited]
Sulfamethoxazole and Trimethoprim Tablets, USP
SULFAMETHOXAZOLE AND TRIMETHOPRIM ORAL SUSPENSION USP FORM NO. 1284/1285 Rev. 3/06 VC2785
Sulfamethoxazole and trimethoprim [Physicians Total Care, Inc.]
Sulfamethoxazole and Trimethoprim Tablets, USP
Septra [Monarch Pharmaceuticals, Inc.]
SEPTRA Tablets SEPTRA DS (Double Strength) Tablets (trimethoprim and sulfamethoxazole)
Clinical Trials
The primary objective of the study is to evaluate the effectiveness of l-leucovorin in preventing toxicity from high dose trimethoprim / sulfamethoxazole (TMP / SMX) used as a therapy for...
To evaluate the effectiveness of two oral treatments for mild to moderate Pneumocystis carinii pneumonia (PCP): dapsone/trimethoprim or clindamycin/primaquine as compared to a standard tr...
To compare the safety and effectiveness of an investigational drug therapy (trimetrexate plus leucovorin calcium) with that of conventional therapy (sulfamethoxazole-trimethoprim) in the t...
Trimethoprim-Sulfamethoxazole or Doxycycline for Skin and Soft Tissue Infections
Background: In many communities, skin and soft tissue infections (SSTI) with MRSA have become more prevalent than infections with β-lactam susceptible bacteria. This has necessitated alt...
To compare the safety and efficacy of two dosage regimens (daily and thrice-weekly) of sulfamethoxazole/trimethoprim (SMX/TMP; TMS) in the prevention of Pneumocystis carinii pneumonia (PCP...
PubMed Articles
Edwardsiella tarda, a catalase-positive bacillus widely distributed throughout nature, is generally susceptible to trimethoprim/sulfamethoxazole. We describe osteomyelitis due to trimethoprim/sulfamet...
BACKGROUND. Although the use of antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) is largely accepted, controversy remains regarding whether the choice...
Failure and relapse after treatment with trimethoprim/sulfamethoxazole in classic Whipple's disease.
Objectives Classic Whipple's disease is a chronic disease caused by Tropheryma whipplei. A recent study reported that intravenous treatment with ceftriaxone or meropenem followed by a 1 year treatment...
Considerations when prescribing trimethoprim-sulfamethoxazole.
Escherichia coli was the most commonly isolated pathogen in the Canadian Ward Surveillance Study 2007-2009 (3789 isolates). Susceptibility to cefazolin (34.1%), trimethoprim-sulfamethoxazole (73.8%),...
